---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-23-002499"
form_type: "8-K"
ticker: "HBIO"
cik: "0001123494"
company_name: "HARVARD BIOSCIENCE INC"
filed_at: "2023-04-25T23:59:59+00:00"
generated_at: "2026-06-16T15:31:31.486590+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Harvard Bioscience Q1 revenue $30M (+4% YoY); net income $0.6M vs $6.9M loss; adj EBITDA margin 16%

## Summary
- Q1 revenues $30.0M, up 4% from $28.8M in Q1'22; gross margin improved to 61% from 56%.
- GAAP net income $0.6M ($0.01 diluted EPS) vs net loss of $6.9M ($0.17 loss) in Q1'22.
- Adjusted EBITDA $4.8M (16% margin) vs $2.7M (9% margin) in prior year.
- Paid down debt by $2.8M; net debt $41.0M; targeting net leverage ~2x by year-end.
- Full-year 2023 guidance: mid-single digit revenue growth, gross margins ~60%, adjusted EBITDA margins 16-17%.

## SEC filing metadata
- accession: 0001171843-23-002499
- form_type: 8-K
- ticker: HBIO
- cik: 0001123494
- company_name: HARVARD BIOSCIENCE INC
- filed_at: 2023-04-25T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1123494/000117184323002499/0001171843-23-002499-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1123494/000117184323002499/f8k_042523.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-23-002499
- JSON: https://secwatch.observer/filing/0001171843-23-002499.json
- Plain text: https://secwatch.observer/filing/0001171843-23-002499.txt

## Key facts
- Earnings Releases
  HARVARD BIOSCIENCE INC reported first quarter ended March 31, 2023 results: revenue $30.0 million, net income $0.6 million, EPS $0.01. Guidance initiated.
  - Period: first quarter ended March 31, 2023
  - Revenue: $30.0 million
  - Net income: $0.6 million
  - EPS: $0.01
  - Guidance: initiated
  - Result: reported results
  source text: a filing. --- EX-99.1 (EXHIBIT 99.1) --- EX-99.1 2 exh_991.htm EXHIBIT 99.1 Exhibit 99.1 Harvard Bioscience Announces First Quarter 2023 Financial Results • Q1 Revenues of $30 million up 4% over prior year period • Q1 GAAP Operating Income of $1.7 million up from a loss of $6.7 million prior year • Q1 Adjusted Operating Income of $4.4 million up from $2.4
  evidence_url: https://www.sec.gov/Archives/edgar/data/1123494/000117184323002499/0001171843-23-002499-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.